Our results showed that HER2 mutations equally mostly co‐existed with HER2 amplification/overexpression, while 21 of 22 (95.5%) performed in ductal carcinoma, and L755S, S310F mutations were the most common. This evidence concerns the gene ERBB2 and breast ductal adenocarcinoma.